Graham Cooke is NIHR Research Professor of Infectious Diseases based within the Department of Infectious Disease at Imperial College and leads the Infection and AMR theme of the Biomedical Research Centre.
A major focus of his research has been to provide the scientific evidence underpinning efforts to eliminate viral hepatitis as a public health threat through investigation of disease burden, modelling, and clinical studies (PROLIFICA and STOPHCV consortia and STOPHCV-1 trial). He currently leads the SEARCH collaboration conducting strategic treatment trials for hepatitis C in Vietnam (in collaboration with OUCRU and MRC Clinical Trials Unit) and the Lancet journals commission on accelerating the elimination of viral hepatitis.
In response to COVID19, he co-ordinated the virtual COVID theme of the NIHR Biomedical Research Centre and was a member of the WHO COVID-19 treatment guidelines group. He led clinical development of the COVIDnudge diagnostic and is a PI for the REACT studies which have recruited over 3 million people to self-testing studies for COVID19.
He is active in promoting access to medicine and patient safety. A member since 2015, he chairs the WHO Committee on the Selection and Use of Essential Medicines, responsible for updating and maintaining the WHO Essential Medicines List (EML) and other areas of medicines use such as the AWaRe index. He was appointed to the Expert groups in HIV and hepatitis (the latter as convenor) for the Infected Blood Inquiry. He is a non-executive director and Deputy Chair of the board of the MHRA.
Funding: NIHR, Wellcome Trust, UKRI, DHSC, Médecins sans Frontières, BRC Imperial College
Follow on twitter: @grahamscooke
(2021) Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C, Wellcome Open Research, Vol:6, Pages:93-9
Simmons B, Cooke GS, Miraldo M (2019) Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis, The Lancet Global Health, Vol:7, ISSN:2214-109X, Pages:e1189-e1196
2019) Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model, The Lancet, Vol:393, ISSN:0140-6736, Pages:1319-1329
2019) Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission, The Lancet Gastroenterology and Hepatology, Vol:4, ISSN:2468-1253, Pages:135-184
2017) Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus, Nature Genetics, Vol:49, ISSN:1546-1718, Pages:666-673
2016) Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia, Scientific Reports, Vol:6, ISSN:2045-2322
2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013, The Lancet, Vol:388, ISSN:0099-5355, Pages:1081-1088
2016) Risk of late relapse or reinfection with Hepatitis C virus after achieving a sustained virological response: A systematic review and meta-analysis, Clinical Infectious Diseases, Vol:62, ISSN:1537-6591, Pages:683-694
2015) Long-term treatment outcomes of patients infected with Hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a Sustained Virological Response, Clinical Infectious Diseases, Vol:61, ISSN:1537-6591, Pages:730-740
2015) Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis, Lancet Infectious Diseases, ISSN:1473-3099
2015) Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus, Hepatology, Vol:61, ISSN:1527-3350, Pages:1174-1182
2015) Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, Vol:61, ISSN:0270-9139, Pages:77-87
Hill AM, Cooke GS, (2014) Hepatitis C can be cured globally, but at what cost?, Science, Vol:345, Pages:141-142
The Lancet Regional Health - Europe, Vol:4, ISSN:2666-7762, Pages:100098-1000982021) Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults,
2021) SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic., Nature Communications, Vol:12, ISSN:2041-1723, Pages:1-8
Moshe M, Daunt A, Flower B, et al (2021) SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (REACT2): diagnostic accuracy study, BMJ, ISSN: 0959-535X
2020) Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study, The Lancet Microbe, Vol:1, ISSN:2666-5247, Pages:e245-e253
2020) A living WHO guideline on drugs for covid-19, BMJ, Vol:370
2020) Usability and acceptability of home-based self-testing for SARS-CoV-2 antibodies for population surveillance., Clinical Infectious Diseases, ISSN:1058-4838
2020) Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 sero-prevalence survey, Thorax, Vol:75, ISSN:0040-6376, Pages:1082-1088
et al., 2021, Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant, Science, Vol:374, ISSN:0036-8075, Pages:1-11
et al., 2021, Predictive symptoms for COVID-19 in the community: REACT-1 study of over one million people, PLOS Medicine, Vol:18, ISSN:1549-1277, Pages:1-14